Shield Therapeutics has signed a marketing partnership for Accrufer in the US and has simultaneously secured its funding position via a combined up to $33.5mln equity and debt fundraising. The twin move transforms Shield's prospects and, in our view, should allow it to capture significantly more va
13 Dec 2022
Prospects transformed with US partnership and debt/equity fundraising
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Prospects transformed with US partnership and debt/equity fundraising
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 15.8m
- Published:
13 Dec 2022 -
Author:
Robin Davison | John Savin PhD | Daniel Appiah -
Pages:
4
Shield Therapeutics has signed a marketing partnership for Accrufer in the US and has simultaneously secured its funding position via a combined up to $33.5mln equity and debt fundraising. The twin move transforms Shield's prospects and, in our view, should allow it to capture significantly more va